Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis.

Glycyrrhetinic acid (GA) shows great efficiency against non-small cell lung cancer (NSCLC), but the detailed mechanism is unclear, which has limited its clinical application. Herein, we investigated the potential targets of GA against NSCLC by activity-based protein profiling (ABPP) technology and the combination of histopathology and proteomics validation. In vitro and in vivo results indicated GA significantly inhibited NSCLC via promotion of peroxiredoxin-6 (Prdx6) and caspase-3 (Casp3)-mediated mitochondrial apoptosis. This original finding will provide theoretical and data support to improve the treatment of NSCLC with the application of GA. Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Citation

Qiuyan Guo, Minghong Zhao, Qixin Wang, Tianming Lu, Piao Luo, Lin Chen, Fei Xia, Huanhuan Pang, Shengnan Shen, Guangqing Cheng, Chuanhao Dai, Yuqing Meng, Tianyu Zhong, Chong Qiu, Jigang Wang. Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Apr;173:116304

Mesh Tags

Substances

PMID: 38401519

search → result